TY - CHAP M1 - Book, Section TI - How to Use and Interpret the Results of a Platform Trial A1 - Park, Jay J. H. A1 - Detry, Michelle A. A1 - Murthy, Srinivas A1 - Guyatt, Gordon A1 - Mills, Edward J. A2 - Guyatt, Gordon A2 - Rennie, Drummond A2 - Meade, Maureen O. A2 - Cook, Deborah J. PY - 2015 T2 - Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice, 3rd ed AB - CLINICAL SCENARIOA hospitalist physician is evaluating a 60-year-old patient with severe COVID-19 who was admitted to the intensive care unit (ICU) and is receiving high-flow oxygen via nasal cannula. A resident physician on the ICU team is considering administration of intravenous hydrocortisone to the patient. The hospitalist physician is requested to assess the evidence regarding that decision. The physician is aware of a platform trial, the Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP), that investigated hydrocortisone vs no hydrocortisone for patients with severe COVID-19.1 REMAP-CAP is an ongoing, international, multicenter platform trial that aims to determine best treatment strategies for patients with severe pneumonia in pandemic and nonpandemic settings.2 This trial is investigating multiple interventions including corticosteroids.The article reporting the corticosteroid findings of the REMAP-CAP trial presented results on organ support–free days, in-hospital mortality, and other clinical outcomes of 2 hydrocortisone regimens vs no hydrocortisone.1 To assess this article, and in particular to determine what inferences can be drawn from platform trials compared with conventional randomized clinical trials (RCTs), the physician uses the framework in the Users’ Guide to Platform Trials (Box 7.2-1). SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/10/12 UR - jamaevidence.mhmedical.com/content.aspx?aid=1193374442 ER -